Breakthrough Clostridium difficile infection in cirrhotic patients receiving rifaximin.

about

Breakthrough Clostridium difficile infection in cirrhotic patients receiving rifaximin.

Item

http://www.wikidata.org/entity/Q50082624

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Breakthrough Clostridium difficile infection in cirrhotic patients receiving rifaximin.

@en

Breakthrough Clostridium difficile infection in cirrhotic patients receiving rifaximin.

@nl

type

Item

label

Breakthrough Clostridium difficile infection in cirrhotic patients receiving rifaximin.

@en

Breakthrough Clostridium difficile infection in cirrhotic patients receiving rifaximin.

@nl

prefLabel

Breakthrough Clostridium difficile infection in cirrhotic patients receiving rifaximin.

@en

Breakthrough Clostridium difficile infection in cirrhotic patients receiving rifaximin.

@nl

P1476

Breakthrough Clostridium difficile infection in cirrhotic patients receiving rifaximin.

@en

P2093

A Martin

http://www.w3.org/2001/XMLSchema#string

J Gómez

http://www.w3.org/2001/XMLSchema#string

L Alcalá

http://www.w3.org/2001/XMLSchema#string

M Marín

http://www.w3.org/2001/XMLSchema#string

P Muñoz

http://www.w3.org/2001/XMLSchema#string

R Onori

http://www.w3.org/2001/XMLSchema#string

P2860

Rifaximin treatment in hepatic encephalopathy

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital.

Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA).

Rifaximin therapy for metronidazole-unresponsive Clostridium difficile infection: a prospective pilot trial.

In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species.

Rifaximin disc diffusion test for in vitro susceptibility testing of Clostridium difficile.

In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004

Clostridium difficile infection in hospitalized liver transplant patients: a nationwide analysis

Use of rifamycin drugs and development of infection by rifamycin-resistant strains of Clostridium difficile.

P31

scholarly article

P356

10.1093/CID/CIX918

http://www.w3.org/2001/XMLSchema#string

P407

English

P50

Emilio Bouza

Elena Reigadas

P577

2017-10-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29069372

http://www.w3.org/2001/XMLSchema#string

P921

Clostridium difficile